(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

Mark David Hartley outlines a strategy he’d use to aim for a second income that gets bigger over time, by investing just £10 a day.

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

GSK announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Professor Matthew Kiernan has won the 2024 GSK Award for Research Excellence for his groundbreaking research into neurodegenerative diseases, including motor neurone disease and frontotemporal ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain ...

Governor Josh Shapiro announced today a $2 million investment in a York County manufacturing company. Earlier today, Governor ...

Dominic Walsh, a business reporter who previously covered the leisure and drinks industry for The Times from 1997 to 2024, stated in post to X: ...